Airway Rescue Algorithm in Procedural Sedation and Analgesia (PSA)

Context

Step 0 — Anticipate Before You Sedate

• Airway assessment: Mallampati score, mouth opening (<4 cm = concern), neck mobility, obesity, facial trauma
• Identify predicted difficult airway — have a lower threshold to involve anesthesia
• Gather equipment at bedside: O₂ source, bag-valve-mask (BVM), suction, oral/nasopharyngeal airways, laryngoscope + ETT, reversal agents (naloxone, flumazenil)
• Assign a dedicated airway/monitoring person — separate from the proceduralist
• Supplemental O₂ preemptively (especially with propofol/deep sedation)
• Capnography connected — detects hypoventilation before SpO₂ drops

The Stepwise Airway Rescue Algorithm

Trigger: Capnography loss of waveform / SpO₂ falling / absent chest rise

STEP 1 — STIMULATE + REPOSITION
  │  Verbally and physically stimulate the patient
  │  Head-tilt/chin-lift OR jaw thrust
  │  Reposition to sniffing position / left lateral if vomiting risk
  │  ↓ If no improvement
  ▼

STEP 2 — AIRWAY ADJUNCTS + SUCTION
  │  Nasopharyngeal airway (NPA) — preferred if gag reflex present
  │  Oropharyngeal airway (OPA) — use if no gag reflex
  │  Suction oropharynx for secretions/blood/vomitus
  │  ↓ If no improvement
  ▼

STEP 3 — BAG-VALVE-MASK (BVM) VENTILATION
  │  Two-person technique (one seals mask, one squeezes bag)
  │  Use cautiously — aggressive BVM → gastric insufflation → vomiting → aspiration
  │  Use ONLY when necessary for oxygenation/ventilation (not reflexively)
  │  ↓ If SpO₂ not recovering or worsening
  ▼

STEP 4 — REVERSAL AGENTS (if applicable)
  │  Opioid-mediated respiratory depression → Naloxone 0.1–0.4 mg IV
  │     (titrate from low end to avoid acute pain/agitation)
  │  Benzodiazepine-mediated depression → Flumazenil 0.2 mg IV
  │     (caution: seizure risk in chronic BZD users; resedation possible at 20–45 min)
  │  Note: No reversal agent for propofol or etomidate — supportive ventilation only
  │  ↓ If failure to recover, persistent apnea, SpO₂ <90% despite above
  ▼

STEP 5 — SUPRAGLOTTIC AIRWAY DEVICE
  │  LMA / i-gel / King LT as a bridge
  │  Rapid to place, no laryngoscopy required
  │  ↓ If cannot ventilate adequately or aspiration suspected
  ▼

STEP 6 — DEFINITIVE AIRWAY: ENDOTRACHEAL INTUBATION
  │  RSI with appropriate induction agent + succinylcholine (or rocuronium)
  │  Video laryngoscopy preferred if available
  │  ↓ If intubation fails (cannot intubate/cannot oxygenate)
  ▼

STEP 7 — SURGICAL AIRWAY RESCUE
     Cricothyrotomy (needle or surgical)
     This is the "cannot intubate, cannot oxygenate" (CICO) endpoint

Special Scenarios Within the Algorithm

Laryngospasm

• Most common trigger: airway secretions, stimulation during light sedation
• Larson's maneuver: firm bilateral pressure in the notch between mastoid and ascending ramus of mandible (laryngospasm notch) — can break partial laryngospasm
• Continuous positive airway pressure via tight mask seal
• If complete laryngospasm persists → succinylcholine 0.1–0.5 mg/kg IV (sub-paralytic "defasciculating" dose) to break spasm
• Full RSI dose (1–1.5 mg/kg) if no response

Rigid Chest Syndrome (Synthetic Opioids)

• Seen with high-dose or rapid-push fentanyl/alfentanil
• Chest wall rigidity → inability to ventilate
• Treatment: succinylcholine (muscle relaxant) + ETT intubation; naloxone generally insufficient alone

Vomiting / Aspiration

• Roll patient to lateral decubitus immediately
• Aggressive suction
• BVM only if oxygenation fails (risk of further aspiration)
• Consider definitive airway if large-volume aspiration

Reversal Agent Dosing Quick Reference

Adverse Event Rates (Tintinalli's, pooled meta-analysis, n = 9,652)

Key Principles to Remember

1. Capnography > pulse oximetry for early detection — SpO₂ lags by 30–60 seconds behind actual apnea
2. Don't grab the BVM first — stimulate, reposition, and use airway adjuncts first; BVM risks aspiration in a spontaneously breathing sedated patient
3. Reversal agents are not routine — reserve for major complications (aspiration risk, hemodynamic collapse, failure to recover)
4. Operator must be airway-capable — PSA should not proceed if the provider cannot manage a failed airway including cricothyrotomy
5. Have the full kit at the bedside before induction — not in the corridor

PSA Monitoring Standards: Recent Clinical Guidelines & Evidence (2024–2026)

Summary of the Evidence Landscape

1. Core Monitoring Parameters (Consensus Across Guidelines: ACEP / ASA / AAP)

2. Highest-Level Recent Evidence (2024–2026)

🔵 [Systematic Review + Meta-Analysis · 2024] Adult PSA Safety in the ED

Drug safety ranking for respiratory events: Ketamine = safest (lowest apnea/hypoxia rates). Propofol = highest hypotension and second-highest hypoxia. Midazolam + opioid combinations = highest apnea rates. Ketamine–propofol combination reduces hypotension, vomiting, bradycardia, and intubation difficulty vs. either drug alone — the strongest pharmacological evidence base supporting this combination.

🔵 [Systematic Review + Meta-Analysis · 2025] Pediatric PSA Safety in the ED

Monitoring conclusion: Careful sedation protocol selection and continuous monitoring are critical. Ketamine combinations show higher rates of specific respiratory complications in peds — warrants heightened vigilance.

🔵 [Systematic Review + Network Meta-Analysis · 2024] Oxygen Delivery for Hypoxemia Prevention

NIPPV > Wei Nasal Jet Tube > Nasopharyngeal catheter > High-flow nasal oxygen > Nasal mask > Standard nasal cannula

• NIPPV was most effective (OR 0.16 vs. nasal cannula, 95% CI 0.08–0.31)
• High-flow nasal oxygen (HFNO) is superior to standard nasal cannula, supporting its use as an upgrade to monitoring + oxygenation strategy in high-risk patients

🔵 [Review · 2024] Capnography for Gastroenterological PSA

• Detects hypoventilation/apnea minutes before pulse oximetry
• Endorsed by multiple society guidelines (ASA, ACEP, ASGE, SGNA)
• Large clinical trials show capnography reduces hypoxemia, severe hypoxemia, and apnea incidence
• Cost of capnography is offset by reduction in adverse events and hospital LOS

🔵 [Review · 2026] Capnography in Pediatric Emergency Care

• ETCO₂ detects hypoventilation ~45 seconds before oxygen desaturation
• Capnography routine use reduces hypoxic episodes and adverse events in pediatric PSA
• Especially recommended for deep sedation with propofol
• Barriers remain: equipment cost, training gaps, lack of universal protocols

🔵 [Best Practice Implementation · 2024] ED Monitoring Compliance

• Baseline ED compliance with evidence-based PSA monitoring: 81%
• After structured implementation intervention: 95%
• Key gaps: end-tidal capnography use, vital sign documentation frequency
• Shows that protocol-driven monitoring significantly improves adherence

3. Current Guideline Monitoring Framework (Three-Phase Model)

Pre-Sedation Phase

• ASA physical status classification
• Fasting status verification (NPO: clear fluids ≥2 h; solid food ≥6 h for elective)
• Informed consent documentation
• Airway risk assessment (Mallampati, mouth opening, neck mobility)
• IV access confirmed; resuscitation equipment at bedside

Intra-Procedural Phase

• Continuous SpO₂, EtCO₂ (capnography), HR, BP, RR, level of consciousness
• Dedicated monitoring person — separate from proceduralist (ACEP Level C)
• Supplemental O₂ applied (upgrade to HFNO for high-risk patients)
• Standardized recording form at regular intervals

Post-Sedation / Recovery Phase

• Continue same monitoring parameters until patient returns to near-baseline
• Aldrete or similar recovery scoring until discharge criteria met
• Vigilance for re-sedation: naloxone wears off at 20–45 min; flumazenil at 45–60 min

4. Key Evidence Gaps & Emerging Areas (2024–2026)

Bottom Line

New Changes in Latest UTI Guidelines (2024–2026)

1. WikiGuidelines UTI Consensus Statement (November 2024)

Key new positions:

2. AUA/CUA/SUFU Guideline Update on Recurrent Uncomplicated UTI in Women (2025)

🔄 Paradigm shift: Away from "detect microbe → treat" toward clinical judgement

"A paradigm shift away from microbial detection to reliance on clinician judgement when weighing the individual risks and benefits of antibiosis."

Expanded non-antibiotic prophylaxis options (newly formalized):

• D-mannose — first-line nonantibiotic option, especially for E. coli-predominant rUTI
• Probiotics — recognized preventive role
• Cranberry — retains a role, particularly in premenopausal women
• UTI vaccines (e.g., Urovac, OM-89/Uromune) — now included in the evidence landscape
• Vaginal estrogen (postmenopausal women) — continues as first-line non-antibiotic prophylaxis

Antibiotic prophylaxis — "collateral damage" framing:

• Guideline now explicitly frames antibiotic prophylaxis risk not just as individual adverse effects but as "collateral damage" — contribution to resistance, microbiome disruption, C. difficile risk
• Antibiotic prophylaxis should be last-resort after non-antibiotic options trialled

3. Treatment Duration: Shorter Is Now Equivalent

Uncomplicated cystitis — no change (still 3–5 days for nitrofurantoin/fosfomycin)

Pyelonephritis and complicated UTI — major update:

5–7 days = 10–14 days for pyelonephritis and febrile complicated UTI (clinical success RR 1.01, 95% CI 0.98–1.04; moderate-certainty evidence)

• No significant difference in microbiological cure, relapse, reinfection, adverse events, or mortality
• Applies to quinolone-treated and physician-selected antibiotic regimens
• Also applies in patients with bacteraemia (57% of the cohort had positive blood cultures)

4. Antibiotic Selection: Fosfomycin Elevated; Fluoroquinolones Further Demoted

Updated first-line preference:

1. Nitrofurantoin (5 days, 100 mg MR twice daily) — if GFR >30
2. Fosfomycin (3 g single dose) — highest cure + safety profile
3. TMP-SMX (3 days) — where local resistance <20%
4. Fluoroquinolones — explicitly not first-line, reserved for complicated UTI or culture-directed therapy only

5. NSAIDs as Antibiotic-Sparing Therapy — Cochrane 2024: Not Recommended as Replacement

• Less short-term symptom resolution with NSAIDs (RR 0.67, 95% CI 0.49–0.91; moderate certainty)
• Longer duration of symptoms (mean 1 extra day)
• NSAIDs result in lower microbiological cure rates and higher progression to pyelonephritis
• No significant difference in adverse events

6. Non-Antibiotic Prophylaxis: D-Mannose Best of the Non-Antibiotic Options

7. Special Populations: Updated Guidance

Older/Frail Adults (EAU-aligned, 2024) — PMID: 39217017

• Asymptomatic bacteriuria in older adults: do NOT treat — reinforced
• UTI diagnosis in frail elderly must use a holistic algorithm including nonspecific symptoms (confusion, functional decline) — but these alone are insufficient for diagnosis without corroborating urinalysis
• Polypharmacy interactions must guide antibiotic selection

Pediatrics (Spanish 2024, Indian Pediatric Nephrology 2024)

• Short-course therapy (3–4 days) now equivalent to longer courses for lower UTI in children [PMID: 38451294]
• Ultrasound ± MCUG recommendations refined — DMSA scan timing updated

Catheter-Associated UTI (CAUTI)

• Systematic review (2024) reveals the evidence base for routine catheter replacement at time of CAUTI treatment is weak — only 4 studies, conflicting results [PMID: 38916643]
• CAUTI remains the most common healthcare-associated infection; prevention (avoidance of unnecessary catheterisation) remains the priority

8. Urinalysis and Microbiology: EFLM 2023 Guideline (Published 2024)

• Chromogenic agar now the recommended primary medium for urine cultures
• MALDI-TOF mass spectrometry recommended for rapid uropathogen identification
• New uropathogens added to the recognised list: Aerococcus urinae, A. sanguinicola, Actinotignum schaalii
• Leukocyturia used to triage which cultures need full antimicrobial susceptibility testing — reduces unnecessary reporting

Summary of Key Practice Changes